放射性标记的(4-氟-3-碘苄基)胍改善去甲肾上腺素转运体表达肿瘤的显像与靶向放射性核素治疗
本研究提出两步放射合成法获得18F-FIBG,并在PC-12嗜铬细胞瘤小鼠模型中评估18F-FIBG和131I-FIBG的诊断与治疗潜力。结果显示18F-FIBG在肿瘤中高摄取,PET图像早至注射后1小时即可清晰显示肿瘤;131I-FIBG在肿瘤中的滞留高于125I-MIBG,治疗剂量131I-FIBG较131I-MIBG更显著延迟肿瘤生长。作者认为FIBG可能作为去甲肾上腺素转运体(NET)表达肿瘤的诊断和治疗药物。
要点
- 18F-FIBG在PC-12移植瘤中摄取高于其他组织,注射后1小时PET即可清晰显示肿瘤。
- 131I-FIBG在肿瘤中的滞留高于且久于125I-MIBG。
- 治疗剂量131I-FIBG较131I-MIBG更显著延迟肿瘤生长。
核心结论
- 作者认为FIBG有潜力作为去甲肾上腺素转运体(NET)表达肿瘤的诊断和治疗药物。
研究设计与样本
- 研究采用两步放射合成法制备18F-FIBG,并在PC-12嗜铬细胞瘤移植瘤小鼠中开展生物分布研究、PET显像和治疗研究。
- 评估了治疗前18F-FIBG PET肿瘤摄取与131I-FIBG治疗效果之间的关联。
主要发现
- 铜介导的放射氟化法可顺利生成18F-FIBG及其区域异构体18F-IFBG。
- 分离的18F-FIBG在PC-12移植瘤中的积累高于任何其他组织,注射后1小时PET图像即可清晰显示肿瘤,肿瘤与本底比优秀。
- 131I-FIBG生物分布研究显示,与125I-MIBG相比,其在肿瘤中滞留更高且更持久。
- 治疗剂量131I-FIBG较131I-MIBG更显著延迟肿瘤生长。
- 18F-FIBG的肿瘤摄取与131I-FIBG的治疗效果成比例。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
18F- or 131I-labeled (4-fluoro-3-iodobenzyl)guanidine (FIBG) has been a promising yet unattainable derivative of radioiodine-labeled meta-iodobenzylguanidine (MIBG), because of the complex radiofluorination method. In this study, we proposed a 2-step radiosynthetic method to obtain 18F-FIBG and evaluated the diagnostic and therapeutic potential of 18F-FIBG and 131I-FIBG in a pheochromocytoma model (PC-12). Methods:18F-FIBG was prepared from a (mesityl)(aryl)iodonium salt precursor in the presence of a copper catalyst. Biodistribution studies, PET imaging, and a therapeutic study were performed on the PC-12 xenograft mice with either 18F- or 131I-FIBG. The association between the therapeutic effect and the tumor uptake of pretherapy 18F-FIBG PET was also evaluated. Results: The copper-mediated radiofluorination method readily yielded 18F-FIBG, as well as its regioisomer, 18F-IFBG. The isolated 18F-FIBG showed a higher accumulation in the PC-12 xenograft tumor than in any other tissue. The high tumor uptake of 18F-FIBG allowed clear tumor visualization in the PET images as early as 1 h after injection, with an excellent tumor-to-background ratio. A biodistribution study with 131I-FIBG revealed its higher and prolonged retention in the tumor in comparison with 125I-MIBG. As a result, a therapeutic dose of 131I-FIBG delayed tumor growth significantly more than did 131I-MIBG. The tumor uptake of 18F-FIBG was proportional to the therapeutic effect of 131I-FIBG. Conclusion: These results suggest the potential usefulness of FIBG as a diagnostic and therapeutic agent for the management of norepinephrine transporter (NET)-expressing tumors.
引用
- Yamaguchi A, Hanaoka H, Higuchi T, et al. Radiolabeled (4-Fluoro-3-Iodobenzyl)Guanidine Improves Imaging and Targeted Radionuclide Therapy of Norepinephrine Transporter-Expressing Tumors. J Nucl Med. 2017. PMID: 29217738. doi:10.2967/jnumed.117.201525
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。